Myelin Oligodendrocyte Glycoprotein (MOG 35-55), 25 mg

Purified myelin oligodendrocyte glycoprotein (MOG) for MOG-induced EAE models in mouse and rat.  Multiple Sclerosis (MS) is a demyelinating disease of the central nervous system (CNS). The main characteristics of the...

Protein

3038001

To request a quote or place an order: Click here

For research use only. Not for use in diagnostic procedures.

Purified myelin oligodendrocyte glycoprotein (MOG) for MOG-induced EAE models in mouse and rat. 

Multiple Sclerosis (MS) is a demyelinating disease of the central nervous system (CNS). The main characteristics of the disease are focal areas of demyelination and inflammation, however the pathogenesis is unclear. Although no animal model thus far establishes all facets of human MS, Experimental Autoimmune Encephalomyelitis (EAE) represents the model most studied for the disease. Initially brain homogenates were used as antigens for immunization. Today, myelin related proteins or peptides are used in the disease.

 

References/Citations:

Gauthier, T., Martin-Rodriguez, O., Chagué, C., Daoui, A., Ceroi, A., Varin, A., ... & Perruche, S. (2023). Amelioration of experimental autoimmune encephalomyelitis by in vivo reprogramming of macrophages using pro-resolving factors. Journal of Neuroinflammation, 20(1), 307.

He, Y., Ge, C., Moreno-Giró, À., Xu, B., Beusch, C. M., Sandor, K., ... & Holmdahl, R. (2023). A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis. Nature communications, 14(1), 691.

Hansson, C., Lebrero-Fernández, C., Schön, K., Angeletti, D., & Lycke, N. (2023). Tr1 cell-mediated protection against autoimmune disease by intranasal administration of a fusion protein targeting cDC1 cells. Mucosal Immunology.

Kap, Y. S., van Driel, N., Arends, R., Rouwendal, G., Verolin, M., Blezer, E., ... & 't Hart, B. A. (2015). Immune modulation by a tolerogenic myelin oligodendrocyte glycoprotein (MOG) 10–60 containing fusion protein in the marmoset experimental autoimmune encephalomyelitis model. Clinical & Experimental Immunology, 180(1), 28-39.

Ichikawa, M., Koh, C. S., Inaba, Y., Seki, C., Inoue, A., Itoh, M., ... & Komiyama, A. (1999). IgG subclass switching is associated with the severity of experimental autoimmune encephalomyelitis induced with myelin oligodendrocyte glycoprotein peptide in NOD mice. Cellular immunology, 191(2), 97-104.

Scolding. (1999). Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease. Neuropathology and applied neurobiology, 25(6), 435-458.

Bernard, C. C. A., Johns, T. G., Slavin, A., Ichikawa, M., Ewing, C., Liu, J., & Bettadapura, J. D. (1997). Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis. Journal of molecular medicine, 75, 77-88.

Product Insert (PDF) - Informational use only. Please refer to insert included with product.

Recent References:

Gauthier, T., Martin-Rodriguez, O., Chagué, C., Daoui, A., Ceroi, A., Varin, A., ... & Perruche, S. (2023). In vivo reprogramming of macrophages using pro-resolving factors to resolve experimental CNS inflammation.

Hansson, C., Lebrero-Fernández, C., Schön, K., Angeletti, D., & Lycke, N. (2023). Tr1 cell-mediated protection against autoimmune disease by intranasal administration of a fusion protein targeting cDC1 cells. Mucosal Immunology.

He, Y., Ge, C., Moreno-Giró, À., Xu, B., Beusch, C. M., Sandor, K., ... & Holmdahl, R. (2023). A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis. Nature Communications, 14(1), 691.